Attention Deficit Hyperactivity Disorder Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Report
250 Pages
December 2023
Region: Global
Fairfield Market Research
ID: 5918225

The global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market is poised for substantial expansion, with global revenues reaching approximately US$ 23.3 billion in 2024. The market is expected to reach a valuation of approximately US$ 47 billion by the end of 2031.

Understanding ADHD:

ADHD is a neurobiological behavioral disorder that affects individuals across various age groups, including children, adolescents, and adults. It is characterized by difficulties in focus, hyperactivity, and impulsivity, often attributed to an imbalance in the neurotransmitters dopamine and noradrenaline in the brain. Common medications for ADHD include psychostimulants like methylphenidate and amphetamines, as well as non-psychostimulants like atomoxetine.

Global Prevalence and Impact:

ADHD is a significant public health concern worldwide, with a high incidence rate, affecting approximately 5–10% of adolescents and children. While most research focuses on children aged 7 to 17, it is essential to note that adults can also have ADHD. The disorder poses significant challenges to academic, interpersonal, and professional performance.

Market Growth Drivers:

The demand for ADHD therapeutics is driven by the following factors:

1. Rising Awareness and Diagnosis: Increasing awareness of ADHD, coupled with improved diagnostic methods, is contributing to the growing demand for ADHD therapeutics.
2. Genetic Component: Numerous studies have highlighted the genetic component of ADHD, leading to increased research and investment in developing effective treatments.

Market Expansion Opportunities:

"Establishment of Adjuvant Therapies"

While drug therapy is the primary treatment for ADHD, there is a rising interest in non-pharmaceutical treatments, such as behavioral therapy and digital therapy (DTx), to complement drug therapy.

Market Growth Challenges:

"Side-Effects and Limitations of Current Therapies"

Pharmacological therapies for ADHD may have side effects, including insomnia, lack of appetite, or nausea. Additionally, behavioral interventions have limitations, and children with ADHD often do not exhibit normalized behavioral function with behavior therapy alone.

Why the U.S. Market is Thriving:

The U.S. market for ADHD therapeutics is witnessing growth due to the rising incidence of adults with ADHD and the expansion of the biopharmaceutical industry.

Germany as a Lucrative Market:

Germany is becoming an attractive market for ADHD therapeutics, with an increasing focus on the underdiagnosed cases of ADHD in adults.

China's Emergence as a Prominent Market:

China is emerging as a significant player in the global ADHD therapeutics market, with growing investments in ADHD research and the presence of regional market players.

Competitive Landscape:

Key companies in the industry are focused on developing novel ADHD drugs and expanding their market shares through mergers, acquisitions, and outsourcing production to reduce costs.

Key Companies Profiled:

Pfizer Inc.
Eli Lilly and Company
Novartis AG
GlaxoSmithKline PLC
Mallinckrodt Pharmaceuticals
Hisamitsu Pharmaceutical Co., Inc.
Johnson & Johnson
UCB S.A.
Purdue Pharma L.P.

Market Segmentation

Drug:

Stimulants
Amphetamine
Methylphenidate
Dextroamphetamine
Dexmethylphenidate
Lisdexamfetamine Dimesylate
Non-stimulants
Atomoxetine
Bupropion
Guanfacine
Clonidine

Age Group:

Pediatric and Adolescent
Adults

Distribution Channel:

Specialty Clinics
Hospital Pharmacies
Retail Pharmacies
E-Commerce

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

This product will be delivered within 1-3 business days.

1. Executive Summary

1.1. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, 2018 - 2031

3.1. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Stimulants
3.1.1.1.1. Amphetamine
3.1.1.1.2. Methylphenidate
3.1.1.1.3. Dextroamphetamine
3.1.1.1.4. Dexmethylphenidate
3.1.1.1.5. Lisdexamfetamine Dimesylate
3.1.1.2. Non-stimulants
3.1.1.2.1. Atomoxetine
3.1.1.2.2. Bupropion
3.1.1.2.3. Guanfacine
3.1.1.2.4. Clonidine
3.2. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Pediatric and Adolescent
3.2.1.2. Adults
3.3. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Specialty Clinics
3.3.1.2. Hospital Pharmacies
3.3.1.3. Retail Pharmacies
3.3.1.4. E-Commerce
3.4. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa

4. North America Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, 2018 - 2031

4.1. North America Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Stimulants
4.1.1.1.1. Amphetamine
4.1.1.1.2. Methylphenidate
4.1.1.1.3. Dextroamphetamine
4.1.1.1.4. Dexmethylphenidate
4.1.1.1.5. Lisdexamfetamine Dimesylate
4.1.1.2. Non-stimulants
4.1.1.2.1. Atomoxetine
4.1.1.2.2. Bupropion
4.1.1.2.3. Guanfacine
4.1.1.2.4. Clonidine
4.2. North America Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Pediatric and Adolescent
4.2.1.2. Adults
4.3. North America Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Specialty Clinics
4.3.1.2. Hospital Pharmacies
4.3.1.3. Retail Pharmacies
4.3.1.4. E-Commerce
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
4.4.1.2. U.S. Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
4.4.1.3. U.S. Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.4.1.4. Canada Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
4.4.1.5. Canada Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
4.4.1.6. Canada Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, 2018 - 2031

5.1. Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Stimulants
5.1.1.1.1. Amphetamine
5.1.1.1.2. Methylphenidate
5.1.1.1.3. Dextroamphetamine
5.1.1.1.4. Dexmethylphenidate
5.1.1.1.5. Lisdexamfetamine Dimesylate
5.1.1.2. Non-stimulants
5.1.1.2.1. Atomoxetine
5.1.1.2.2. Bupropion
5.1.1.2.3. Guanfacine
5.1.1.2.4. Clonidine
5.2. Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Pediatric and Adolescent
5.2.1.2. Adults
5.3. Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Specialty Clinics
5.3.1.2. Hospital Pharmacies
5.3.1.3. Retail Pharmacies
5.3.1.4. E-Commerce
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
5.4.1.2. Germany Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
5.4.1.3. Germany Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.4. U.K. Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
5.4.1.5. U.K. Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
5.4.1.6. U.K. Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.7. France Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
5.4.1.8. France Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
5.4.1.9. France Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.10. Italy Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
5.4.1.11. Italy Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
5.4.1.12. Italy Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.13. Turkey Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
5.4.1.14. Turkey Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
5.4.1.15. Turkey Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.16. Russia Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
5.4.1.17. Russia Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
5.4.1.18. Russia Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.19. Rest of Europe Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
5.4.1.20. Rest of Europe Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
5.4.1.21. Rest of Europe Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, 2018 - 2031

6.1. Asia Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Stimulants
6.1.1.1.1. Amphetamine
6.1.1.1.2. Methylphenidate
6.1.1.1.3. Dextroamphetamine
6.1.1.1.4. Dexmethylphenidate
6.1.1.1.5. Lisdexamfetamine Dimesylate
6.1.1.2. Non-stimulants
6.1.1.2.1. Atomoxetine
6.1.1.2.2. Bupropion
6.1.1.2.3. Guanfacine
6.1.1.2.4. Clonidine
6.2. Asia Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Pediatric and Adolescent
6.2.1.2. Adults
6.3. Asia Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Specialty Clinics
6.3.1.2. Hospital Pharmacies
6.3.1.3. Retail Pharmacies
6.3.1.4. E-Commerce
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
6.4.1.2. China Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
6.4.1.3. China Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.4. Japan Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
6.4.1.5. Japan Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
6.4.1.6. Japan Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.7. South Korea Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
6.4.1.8. South Korea Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
6.4.1.9. South Korea Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.10. India Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
6.4.1.11. India Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
6.4.1.12. India Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.13. Southeast Asia Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
6.4.1.14. Southeast Asia Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
6.4.1.15. Southeast Asia Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.16. Rest of Asia Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
6.4.1.17. Rest of Asia Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
6.4.1.18. Rest of Asia Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, 2018 - 2031

7.1. Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Stimulants
7.1.1.1.1. Amphetamine
7.1.1.1.2. Methylphenidate
7.1.1.1.3. Dextroamphetamine
7.1.1.1.4. Dexmethylphenidate
7.1.1.1.5. Lisdexamfetamine Dimesylate
7.1.1.2. Non-stimulants
7.1.1.2.1. Atomoxetine
7.1.1.2.2. Bupropion
7.1.1.2.3. Guanfacine
7.1.1.2.4. Clonidine
7.2. Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Pediatric and Adolescent
7.2.1.2. Adults
7.3. Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Specialty Clinics
7.3.1.2. Hospital Pharmacies
7.3.1.3. Retail Pharmacies
7.3.1.4. E-Commerce
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
7.4.1.2. Brazil Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
7.4.1.3. Brazil Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.4. Mexico Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
7.4.1.5. Mexico Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
7.4.1.6. Mexico Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.7. Argentina Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
7.4.1.8. Argentina Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
7.4.1.9. Argentina Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.10. Rest of Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
7.4.1.11. Rest of Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
7.4.1.12. Rest of Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, 2018 - 2031

8.1. Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Stimulants
8.1.1.1.1. Amphetamine
8.1.1.1.2. Methylphenidate
8.1.1.1.3. Dextroamphetamine
8.1.1.1.4. Dexmethylphenidate
8.1.1.1.5. Lisdexamfetamine Dimesylate
8.1.1.2. Non-stimulants
8.1.1.2.1. Atomoxetine
8.1.1.2.2. Bupropion
8.1.1.2.3. Guanfacine
8.1.1.2.4. Clonidine
8.2. Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Pediatric and Adolescent
8.2.1.2. Adults
8.3. Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Specialty Clinics
8.3.1.2. Hospital Pharmacies
8.3.1.3. Retail Pharmacies
8.3.1.4. E-Commerce
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
8.4.1.2. GCC Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
8.4.1.3. GCC Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.4. South Africa Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
8.4.1.5. South Africa Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
8.4.1.6. South Africa Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.7. Egypt Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
8.4.1.8. Egypt Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
8.4.1.9. Egypt Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.10. Nigeria Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
8.4.1.11. Nigeria Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
8.4.1.12. Nigeria Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.13. Rest of Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market by Drug, Value (US$ Bn), 2018 - 2031
8.4.1.14. Rest of Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
8.4.1.15. Rest of Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Manufacturer vs By Drug Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Pfizer Inc.
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Eli Lilly and Company
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Novartis AG
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. GlaxoSmithKline PLC
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Mallinckrodt Pharmaceuticals
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Hisamitsu Pharmaceutical Co., Inc.
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Johnson & Johnson
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. UCB S.A.
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. Purdue Pharma L.P.
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Pfizer Inc.
Eli Lilly and Company
Novartis AG
GlaxoSmithKline PLC
Mallinckrodt Pharmaceuticals
Hisamitsu Pharmaceutical Co., Inc.
Johnson & Johnson
UCB S.A.
Purdue Pharma L.P.

Methodology

LOADING...